Amprius Technologies, Inc. (AMPX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Amprius Technologies, Inc. develops and manufactures high-energy density lithium-ion batteries using silicon anode technology for mobility applications, primarily in aviation (drones, UAS), electric vehicles (EV), and light electric vehicles (LEV). The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $21,426 | $7,855 | $47,777 | $13,536 |
| Gross Profit | $3,318 | $(5,101) | $2,297 | $(16,077) |
| Gross Margin | 15.5% | (65.0%) | 4.8% | (118.8%) |
| Net Loss | $(3,892) | $(10,850) | $(19,633) | $(33,253) |
| Net Loss Per Share (Basic/Diluted) | $(0.03) | $(0.10) | $(0.16) | $(0.34) |
| Cash and Cash Equivalents | $73,224 | $55,155 | (Balance Sheet) | |
| Operating Cash Flow (9M) | $(27,637) | $(27,267) | ||
| Financing Cash Flow (9M) | $47,952 | $24,585 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 173% year-over-year (YoY) in Q3 and 253% YoY for the nine-month period. This was driven primarily by a significant increase in sales of SiCore batteries and the acquisition of 80 new customers in Q3 2025.
- Profitability Improvement: The company achieved a gross profit of $3.3 million in Q3 2025, compared to a gross loss of $5.1 million in Q3 2024. This turnaround is attributed to higher sales volumes and improved product mix.
- Expense Increases: Operating expenses rose 30% in Q3 and 27% for the nine-month period, primarily due to increased personnel-related costs (including stock-based compensation) and professional fees to support business scaling.
- Liquidity Position: Cash and cash equivalents increased to $73.2 million as of September 30, 2025, from $55.2 million at year-end 2024, bolstered by $44.1 million in net proceeds from equity issuances under the At Market Issuance Sales Agreement during the nine months ended September 30, 2025.
Guidance, Outlook, and Risks
- Manufacturing Expansion: The company is expanding capacity at its Fremont, California facility with support from a $12.0 million U.S. Government Defense Innovation Unit contract awarded in July 2025. Deliveries of SiCore cells manufactured in Fremont have commenced.
- Brighton Facility: Pre-construction planning for a GWh-scale facility in Brighton, Colorado, was completed in 2024. However, the scope and schedule depend on funding availability. The company is currently exploring the potential sublease of all or part of this facility.
- Capital Resources: Management believes current cash reserves are sufficient to fund operations for at least 12 months. Approximately $20.1 million remains available under the At Market Issuance Sales Agreement.
- Risks: Key risks include reliance on third-party manufacturers (specifically Berzelius and partners in China/South Korea) for SiCore production, potential supply chain disruptions due to geopolitical tensions or tariffs, and the need for significant capital to scale manufacturing to commercial volumes. The company also faces risks related to product performance, safety, and intellectual property protection.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the single customer representing 35% of revenue in Q3 2025 and the top two customers representing 64% of accounts receivable.
- Supply Chain Dependencies: Assess the terms and reliability of the Exclusive Supply Agreement with Berzelius and the capacity constraints of contract manufacturers in China and South Korea.
- Brighton Facility Status: Confirm the decision-making timeline regarding the construction or subleasing of the Brighton, Colorado facility and its impact on future capital expenditures.
- Government Contract Utilization: Monitor the utilization of the $12.0 million Defense Innovation Unit contract and its impact on Fremont facility expansion.
- Warrant Exercise Potential: Evaluate the likelihood of warrant exercises given the current stock price relative to the $11.50 (public/private) and $12.50 (PIPE) exercise prices.